{"$schema":"https://www.lobbyregister.bundestag.de/json-schemas/R2.22/Lobbyregister-Registereintrag-schema-R2.22.json","source":"Deutscher Bundestag, Lobbyregister für die Interessenvertretung gegenüber dem Deutschen Bundestag und der Bundesregierung","sourceUrl":"https://www.lobbyregister.bundestag.de","sourceDate":"2026-04-07T17:56:18.188+02:00","jsonDocumentationUrl":"https://www.lobbyregister.bundestag.de/informationen-und-hilfe/open-data-1049716","registerNumber":"R007599","registerEntryDetails":{"registerEntryId":65380,"legislation":"GL2024","version":2,"detailsPageUrl":"https://www.lobbyregister.bundestag.de/suche/R007599/65380","pdfUrl":"https://www.lobbyregister.bundestag.de/media/34/18/638871/Lobbyregister-Registereintraege-Detailansicht-R007599-2025-11-13_12-13-37.pdf","validFromDate":"2025-11-13T12:13:37.000+01:00","fiscalYearUpdate":{"updateMissing":false}},"accountDetails":{"activeLobbyist":true,"activeDateRanges":[{"fromDate":"2025-09-16T13:54:10.000+02:00"}],"firstPublicationDate":"2025-09-16T13:54:10.000+02:00","lastUpdateDate":"2025-11-13T12:13:37.000+01:00","registerEntryVersions":[{"registerEntryId":65380,"jsonDetailUrl":"https://www.lobbyregister.bundestag.de/sucheJson/R007599/65380","version":2,"legislation":"GL2024","validFromDate":"2025-11-13T12:13:37.000+01:00","versionActiveLobbyist":true},{"registerEntryId":61810,"jsonDetailUrl":"https://www.lobbyregister.bundestag.de/sucheJson/R007599/61810","version":1,"legislation":"GL2024","validFromDate":"2025-09-16T13:54:10.000+02:00","validUntilDate":"2025-11-13T12:13:37.000+01:00","versionActiveLobbyist":true}],"accountHasCodexViolations":false},"lobbyistIdentity":{"identity":"ORGANIZATION","name":"Madrigal Pharmaceuticals Deutschland GmbH","legalFormType":{"code":"JURISTIC_PERSON","de":"Juristische Person","en":"Legal person"},"legalForm":{"code":"LF_GMBH","de":"Gesellschaft mit beschränkter Haftung (GmbH)","en":"Limited liability company (GmbH)"},"contactDetails":{"phoneNumber":"+491733194732","emails":[{"email":"Imohr@madrigalpharma.com"},{"email":"tloechle@madrigalpharma.com"}],"websites":[{"website":"www.madrigalpharma.com"}]},"address":{"type":"NATIONAL","nationalAdditional1":"c/o Mindspace","street":"Herzogspitalstraße ","streetNumber":"24","zipCode":"80331","city":"München","country":{"code":"DE","de":"Deutschland","en":"Germany"}},"capitalCityRepresentationPresent":false,"legalRepresentatives":[{"lastName":"Löchle","firstName":"Thorsten","function":"Geschäftsführer","recentGovernmentFunctionPresent":false,"entrustedPerson":true,"contactDetails":{}}],"entrustedPersonsPresent":true,"entrustedPersons":[{"lastName":"Löchle","firstName":"Thorsten","recentGovernmentFunctionPresent":false},{"lastName":"Capewell","firstName":"Melanie","recentGovernmentFunctionPresent":false},{"lastName":"Michael","firstName":"Simang","recentGovernmentFunctionPresent":false},{"lastName":"Mohr","firstName":"Inamarie","recentGovernmentFunctionPresent":false}],"membersPresent":false,"membershipsPresent":false},"activitiesAndInterests":{"activity":{"code":"ACT_ORGANIZATION_V2","de":"Sonstiges Unternehmen","en":"Other company"},"typesOfExercisingLobbyWork":[{"code":"SELF_OPERATED_OWN_INTEREST","de":"Die Interessenvertretung wird in eigenem Interesse selbst wahrgenommen","en":"Interest representation is self-performed in its own interest"},{"code":"CONTRACTS_OPERATED_BY_THIRD_PARTY","de":"Die Interessenvertretung wird in eigenem Interesse durch die Beauftragung Dritter wahrgenommen","en":"Contracts are awarded to third parties to represent own interests of the company"}],"fieldsOfInterest":[{"code":"FOI_SCIENCE_RESEARCH_TECHNOLOGY","de":"Wissenschaft, Forschung und Technologie","en":"Science, research and technology"},{"code":"FOI_HEALTH_OTHER","de":"Sonstiges im Bereich \"Gesundheit\"","en":"Other in the field of \"Health\""},{"code":"FOI_HEALTH_MEDICINE","de":"Arzneimittel","en":"Medicine"},{"code":"FOI_HEALTH_PROMOTION","de":"Gesundheitsförderung","en":"Health promotion"},{"code":"FOI_ECONOMY_INDUSTRIAL","de":"Industriepolitik","en":"Industrial policy"}],"activityDescription":"Madrigal Pharmaceuticals Deutschland GmbH ist ein biopharmazeutisches Unternehmen, das sich auf die Bereitstellung neuartiger Therapeutika für die metabolische Dysfunktion-assoziierte Steatohepatitis (MASH) spezialisiert hat, eine Lebererkrankung mit hohem ungedecktem medizinischem Bedarf.\r\n\r\nWir sehen es als Teil unserer unternehmerischen Verantwortung, Patientinnen und Patienten mit entsprechender medizinischer Indikation einen schnellen und gerechten Zugang zu neuen Behandlungsmöglichkeiten zu ermöglichen.\r\n\r\nDazu suchen wir den Dialog mit politischen Entscheidungsträgerinnen und -trägern, unter anderem in Form von Gesprächen, Fachveranstaltungen und Positionspapieren. Unser Ziel ist es, zu verlässlichen und innovationsfreundlichen Rahmenbedingungen im Gesundheitswesen beizutragen."},"employeesInvolvedInLobbying":{"relatedFiscalYearFinished":true,"relatedFiscalYearStart":"2024-09-09","relatedFiscalYearEnd":"2024-12-31","employeeFTE":0.0},"financialExpenses":{"relatedFiscalYearFinished":true,"relatedFiscalYearStart":"2024-09-09","relatedFiscalYearEnd":"2024-12-31","financialExpensesEuro":{"from":0,"to":0}},"mainFundingSources":{"relatedFiscalYearFinished":true,"relatedFiscalYearStart":"2024-09-09","relatedFiscalYearEnd":"2024-12-31","mainFundingSources":[{"code":"MFS_OTHERS","de":"Sonstiges","en":"Others"},{"code":"MFS_ECONOMIC_ACTIVITY","de":"Wirtschaftliche Tätigkeit","en":"Economic activity"}]},"publicAllowances":{"publicAllowancesPresent":false,"relatedFiscalYearFinished":true,"relatedFiscalYearStart":"2024-09-09","relatedFiscalYearEnd":"2024-12-31"},"donators":{"relatedFiscalYearFinished":true,"relatedFiscalYearStart":"2024-09-09","relatedFiscalYearEnd":"2024-12-31","totalDonationsEuro":{"from":0,"to":0}},"membershipFees":{"relatedFiscalYearFinished":true,"relatedFiscalYearStart":"2024-09-09","relatedFiscalYearEnd":"2024-12-31","totalMembershipFees":{"from":0,"to":0},"individualContributorsPresent":false,"individualContributors":[]},"annualReports":{"annualReportPreviousLastFiscalYearExists":false},"regulatoryProjects":{"regulatoryProjectsPresent":true,"regulatoryProjectsCount":2,"regulatoryProjects":[{"regulatoryProjectNumber":"RV0020649","title":"Weiterentwicklung des AMNOG Verfahrens für innovative und neuartige Therapien","printedMattersPresent":false,"printedMatters":[],"draftBillPresent":false,"description":"Verbesserung der Rahmenbedingungen für innovative und neuartige Arzneimittel im AMNOG Verfahren","affectedLawsPresent":true,"affectedLaws":[{"title":"Sozialgesetzbuch (SGB) Fünftes Buch (V) - Gesetzliche Krankenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477)","shortTitle":"SGB 5","url":"https://www.gesetze-im-internet.de/sgb_5"}],"fieldsOfInterest":[{"code":"FOI_SCIENCE_RESEARCH_TECHNOLOGY","de":"Wissenschaft, Forschung und Technologie","en":"Science, research and technology"},{"code":"FOI_HEALTH_MEDICINE","de":"Arzneimittel","en":"Medicine"},{"code":"FOI_HEALTH_PROMOTION","de":"Gesundheitsförderung","en":"Health promotion"},{"code":"FOI_HEALTH_OTHER","de":"Sonstiges im Bereich \"Gesundheit\"","en":"Other in the field of \"Health\""}]},{"regulatoryProjectNumber":"RV0020650","title":"Früherkennung und präventive Versorgung chronischer Erkrankungen ","printedMattersPresent":false,"printedMatters":[],"draftBillPresent":false,"description":"Frühzeitige Erkennung von chronischen Krankheiten und deren Prävention, insbesondere im Bereich der Erkrankungen der Leber, z.B. MASH. ","affectedLawsPresent":true,"affectedLaws":[{"title":"Sozialgesetzbuch (SGB) Fünftes Buch (V) - Gesetzliche Krankenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477)","shortTitle":"SGB 5","url":"https://www.gesetze-im-internet.de/sgb_5"}],"fieldsOfInterest":[{"code":"FOI_HEALTH_PROMOTION","de":"Gesundheitsförderung","en":"Health promotion"}]}]},"statements":{"statementsPresent":false,"statementsCount":0,"statements":[]},"contracts":{"contractsPresent":false,"contractsCount":0,"contracts":[]},"codeOfConduct":{"ownCodeOfConduct":false}}